Trials / Sponsors / Atara Biotherapeutics
Atara Biotherapeutics
Industry · 8 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythem Lupus Nephritis, Systemic Lupus Erythematosus | Phase 1 | 2025-04-16 |
| Terminated | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | 2024-09-06 |
| Terminated | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections | Phase 1 / Phase 2 | 2019-02-19 |
| Terminated | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | 2017-10-19 |
| Completed | Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partial EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma | Phase 2 | 2011-12-01 |
| Completed | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Maligna EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma | Phase 1 / Phase 2 | 1995-03-01 |
| No Longer Available | Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignan Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma | — | — |
| No Longer Available | Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Di CMV Viremia, CMV Disease | — | — |